Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
November 9, 2026
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
November 5, 2026
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
November 3, 2026
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
October 29, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
October 26, 2026
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 2, 2026
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
1
2
Next Page
→